HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

4th Edition of World Congress on Infectious Diseases

June 21-22, 2023 | Rome, Italy

June 21 -22, 2023 | Rome, Italy
Infection 2023

Micaela J.San Diego

Speaker at World Congress on Infectious Diseases 2023 - Micaela J.San Diego
San Lazaro Hospital, Philippines
Title : Relative risk of disease severity and disease outcomes with serotype-specific dengue virus among hospitalized dengue patients in a tertiary infectious diseases hospital: A five-year retrospective study


Dengue fever is a significant cause of morbidity throughout the world caused by the dengue virus (DENV). Four antigenically different dengue virus serotypes (DENV-1,2,3, and 4) are known to cause infections in humans (Halsey,2012). Chances for developing dengue hemorrhagic fever-dengue shock syndrome increases significantly with history of previous infection with one of the four serotypes.

General Objective: To determine the relative risk of disease severity, and disease outcomes of serotype-specific dengue virus among hospitalized dengue patients at San Lazaro Hospital from 2015-2019.

A retrospective study of hospitalized dengue patients in span of five years was done. One-hundred forty three (143) patients aged >19 years admitted due to fever, positive for NS1 antigen and with DENV serotype results were included. Clinical data were extracted from medical records including demographics, co-morbidities, clinical presentation, laboratory investigations, length of hospital stay and outcome.

Results: Out of the 143 adult dengue patients, the most prevalent serotype was DENV 3 at 64.34% followed by DENV 2 (18.18%), DENV 1 (11.19%), with DENV 4 as the least prevalent serotype (6.29%). In terms of clinical manifestations, the most prevalent symptoms were fever (98.60%), myalgia (78.32%), body malaise (69.23%), headache (59.44%), nausea and vomiting in 42.66%. Majority tested positive for Dengue NS1 (87.94%), with more than half testing positive for Dengue IgG at 54.24%. The adjusted risk for dengue with warning signs for DENV-2 was 5.94, indicating that the risk of dengue with warning signs was 5.94 times higher among those with DENV 2 than those with DENV 1; however, the association was not statistically significant. Results showed that the ARR for serotypes 3 and 4 for all dengue severity categories were not statistically significant (p>0.05). The clinical outcome of patients was recovery at 98.60%, with only 1.40% mortality. Comparative analyses indicated that the clinical management and outcomes of the patients did not significantly differ according to dengue virus serotype (p>0.05).

Conclusion: This study provided more information on the dengue serotypes, its effect on severity and outcome of the disease. Infecting dengue serotype play an important role in disease severity among adult dengue patients in the Philippines.

1) This research paper determined the most common serotype of DENV in the last five years in the Philippines and its effect on disease severity and outcomes.
2) This study aids in diseases surveillance of DENV especially in endemic countries like the Philippines 3) This will provide avenue for research papers regarding the importance of DENV serotype determination in hospital institutions and different countries in the future. 4) This will promote awareness among healthcare workers when it comes to DENV management


Dr. Micaela J. San Diego finished her Bachelor of Science in Pharmacy from the University of Santo Tomas and finished her Doctor of Medicine from St. Luke’s Medical Center College of Medicine. She completed her residency in Internal Medicine at De Los Santos Medical Center in Quezon City. She is a diplomate and fellow of the Philippine College of Physicians. She finished her fellowship in training last June 2022 from the Adult Infectious Diseases and Tropical Medicine Department at San Lazaro Hospital. Currently she is an Infectious diseases consultant practicing in the province of Bulacan, Philippines.